[1]
Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018, 19(1): 27-39. DOI: 10.1016/S1470-2045(17)30777-5.
[2]
O′HalloranN, LoweryA, CurranC, et al. A Review of the Impact of Neoadjuvant Chemotherapy on Breast Surgery Practice and Outcomes[J]. Clin Breast Cancer, 2019, 19(5): 377-382. DOI: 10.1016/j.clbc.2019.04.011.
[3]
MougalianSS, SoulosPR, KilleleaBK, et al. Use of neoadjuvant chemotherapy for patients with stage Ⅰ to Ⅲ breast cancer in the United States[J]. Cancer, 2015, 121(15): 2544-2552. DOI: 10.1002/cncr.29348.
[4]
VugtsG, Maaskant-BraatAJ, NieuwenhuijzenGA, et al. Patterns of Care in the Administration of Neo-adjuvant Chemotherapy for Breast Cancer. A Population-Based Study[J]. Breast J, 2016, 22(3): 316-321. DOI: 10.1111/tbj.12568.
[5]
SunY, LiaoM, HeL, et al. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Baltimore), 2017, 96(43): e8367. DOI: 10.1097/MD.0000000000008367.
[6]
CortazarP, ZhangL, UntchM, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. DOI: 10.1016/S0140-6736(13)62422-8.
[7]
DominiciLS, Negron GonzalezVM, BuzdarAU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer[J]. Cancer, 2010, 116(12): 2884-2889. DOI: 10.1002/cncr.25152.
[8]
BoileauJF, PoirierB, BasikM, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264. DOI: 10.1200/JCO.2014.55.7827.
[9]
BougheyJC, SumanVJ, MittendorfEA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461. DOI: 10.1001/jama.2013.278932.
[10]
《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组. 中国乳腺癌新辅助治疗专家共识(2022年版)[J]. 中国癌症杂志,2022, 32(1): 80-89.
[11]
FoldiJ, RozenblitM, ParkTS, et al. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy[J]. Curr Treat Options Oncol, 2021, 22(9): 79. DOI: 10.1007/s11864-021-00879-4.
[12]
KennedyBJ, KelleyRM, WhiteG, et al. Surgery as an adjunct to hormone therapy of breast cancer[J]. Cancer, 1957, 10(5): 1055-1075. DOI: 3.0.co;2-x" xlink:type="simple">10.1002/1097-0142(195709/10)10:5<1055::aid-cncr2820100528>3.0.co;2-x.
[13]
De LenaM, VariniM, ZucaliR, et al. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery[J]. Cancer Clin Trials, 1981, 4(3): 229-236.
[14]
FisherB, BrownA, MamounasE, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 15(7): 2483-2493. DOI: 10.1200/JCO.1997.15.7.2483.
[15]
RastogiP, AndersonSJ, BearHD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-785. DOI: 10.1200/JCO.2007.15.0235.
[16]
NekljudovaV, LoiblS, von MinckwitzG, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC)[J]. Contemp Clin Trials, 2018, 71: 194-198. DOI: 10.1016/j.cct.2018.06.016.
[17]
MasudaN, LeeSJ, OhtaniS, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159. DOI: 10.1056/NEJMoa1612645.
[18]
von MinckwitzG, HuangCS, ManoMS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer[J]. N Engl J Med, 2019, 380(7): 617-628. DOI: 10.1056/NEJMoa1814017.
[19]
KesslerAJ, SparanoJA. Systemic therapy for triple-negative breast cancer: a changing landscape[J]. Crit Rev Oncol Hematol, 2022, 171: 103608. DOI: 10.1016/j.critrevonc.2022.103608.
[20]
von MinckwitzG, UntchM, BlohmerJU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(15): 1796-1804. DOI: 10.1200/JCO.2011.38.8595.
[21]
SikovWM, BerryDA, PerouCM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21. DOI: 10.1200/JCO.2014.57.0572.
[22]
DieciMV, Del MastroL, CinquiniM, et al. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)[J]. Cancers (Basel), 2019, 11(8): 1137. DOI: 10.3390/cancers11081137.
[23]
SchneeweissA, MöbusV, TeschH, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase Ⅲ trial[J]. Eur J Cancer, 2019, 106: 181-192. DOI: 10.1016/j.ejca.2018.10.015.
[24]
GianniL, MansuttiM, AntonA, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial[J]. JAMA Oncol, 2018, 4(3): 302-308. DOI: 10.1001/jamaoncol.2017.4612.
[25]
UntchM, JackischC, SchneeweissA, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 345-356. DOI: 10.1016/S1470-2045(15)00542-2.
[26]
LoiblS, O′ShaughnessyJ, UntchM, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(4): 497-509. DOI: 10.1016/S1470-2045(18)30111-6.
[27]
LoiblS, UntchM, BurchardiN, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288. DOI: 10.1093/annonc/mdz158.
[28]
GianniL, HuangCS, EgleD, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study[J]. Ann Oncol, 2022. DOI: 10.1016/j.annonc.2022.02.004.
[29]
SchmidP, CortesJ, PusztaiL, et al. Pembrolizumab for Early Triple-Negative Breast Cancer[J]. N Engl J Med, 2020, 382(9): 810-821. DOI: 10.1056/NEJMoa1910549.
[30]
SpringLM, FellG, ArfeA, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis[J]. Clin Cancer Res, 2020, 26(12): 2838-2848. DOI: 10.1158/1078-0432.CCR-19-3492.
[31]
SlamonDJ, ClarkGM, WongSG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785): 177-182. DOI: 10.1126/science.3798106.
[32]
GianniL, EiermannW, SemiglazovV, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384. DOI: 10.1016/S0140-6736(09)61964-4.
[33]
BuzdarAU, SumanVJ, Meric-BernstamF, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(13): 1317-1325. DOI: 10.1016/S1470-2045(13)70502-3.
[34]
UntchM, RezaiM, LoiblS, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study[J]. J Clin Oncol, 2010, 28(12): 2024-2031. DOI: 10.1200/JCO.2009.23.8451.
[35]
BaselgaJ, BradburyI, EidtmannH, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2012, 379(9816): 633-640. DOI: 10.1016/S0140-6736(11)61847-3.
[36]
GianniL, PienkowskiT, ImYH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32. DOI: 10.1016/S1470-2045(11)70336-9.
[37]
DeyN, AskeJ, DeP. Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCR[J]. Cancers (Basel), 2021, 13(3): 458. DOI: 10.3390/cancers13030458.
[38]
HayashiN, YagataH, TsugawaK, et al. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER(+) HER2(-) Breast Cancer: A Prospective Phase II Study[J]. Clin Breast Cancer, 2020, 20(6): 462-468. DOI: 10.1016/j.clbc.2020.09.007.
[39]
SpringLM, GuptaA, ReynoldsKL, et al. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis[J]. JAMA Oncol, 2016, 2(11): 1477-1486. DOI: 10.1001/jamaoncol.2016.1897.
[40]
EllisMJ, SumanVJ, HoogJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17): 2342-2349. DOI: 10.1200/JCO.2010.31.6950.
[41]
KuterI, GeeJM, HeggR, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study[J]. Breast Cancer Res Treat, 2012, 133(1): 237-246. DOI: 10.1007/s10549-011-1947-7.
[42]
LereboursF, RiveraS, Mouret-ReynierMA, et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)[J]. Cancer, 2016, 122(19): 3032-3040. DOI: 10.1002/cncr.30143.
[43]
WalkerAJ, WedamS, Amiri-KordestaniL, et al. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer[J]. Clin Cancer Res, 2016, 22(20): 4968-4972. DOI: 10.1158/1078-0432.CCR-16-0493.
[44]
ShahA, BloomquistE, TangS, et al. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer[J]. Clin Cancer Res, 2018, 24(13): 2999-3004. DOI: 10.1158/1078-0432.CCR-17-2369.
[45]
PetrelliF, GhidiniA, PedersiniR, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials[J]. Breast Cancer Res Treat, 2019, 174(3): 597-604. DOI: 10.1007/s10549-019-05133-y.
[46]
MedfordA, SpringLM, MoyB, et al. Antibody drug conjugates for patients with breast cancer[J]. Curr Probl Cancer, 2021, 45(5): 100795. DOI: 10.1016/j.currproblcancer.2021.100795.
[47]
VarnierR, SajousC, de TalhouetS, et al. Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives[J]. Cancers (Basel), 2021, 13(19): 4840. DOI: 10.3390/cancers13194840.
[48]
李健斌,江泽飞. 早期乳腺癌治疗10个热点问题的冷思考[J]. 中华外科杂志,2022, 60(3): 213-218. DOI: 10.3760/cma.j.cn112139-20211010-00482.